Malaria Prophylaxis in Different Age Groups.
Background: There is a perceived increased health risk in senior visitors to malaria endemic countries. Methods: The authors sought to compare effectiveness and tolerability of malaria chemoprophylaxis in senior travelers (>=60 years) with those in younger travelers (20-59 years). The "Malpro 2" database consists of more than 100,000 questionnaires completed by travelers on charter planes returning from East Africa to Europe during July 1988-December 1991. Among them, 9106 (9.1%) of the travelers were 60 years or older, and 84,562 (84.6%) of the travelers reported to be 20-59 years. Variables of demography, travel data, and the effectiveness and tolerability of chemoprophylaxis were compared in the two subgroups. Results: Malaria in Africa was reported by 8 (1/1000) elderly travelers and by 189 (2.2/1000) travelers aged 20-59 years. Adjusting for age, sex, prophylaxis, and duration of stay in Africa in a logistic regression model, malaria was significantly more frequent in younger than in senior travelers (p<.05). Any travel-associated illness was reported by 7.0% in the senior age group and by 13.6% in the younger age group (p<.05). The rates of travelers who indicated they had "side effects" attributable to malaria prophylaxis varied between 9.7% in the elderly and 15.5% in the younger travelers (p<.05). Conclusion: Senior travelers tolerate malaria chemoprophylaxis and visits to the tropics at least as well as younger travelers.
Mittelholzer
ML
Pharmaceuticals Division, Business Development & Strategic Marketing, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Wall
M
Steffen
R
Stürchler
D